XOVR Outperforms Growth Benchmarks Since SpaceX IPO

ERShares' Private-Public Crossover ETF (XOVR) returned 5.64% from the June 12, 2026 SpaceX IPO through September 4, outperforming the Russell 1000 Growth Index's 1.64% and the Nasdaq-100's 0.47%. Since its August 2024 relaunch, XOVR delivered a 40.42% cumulative NAV return, exceeding Russell 1000 Growth by 224bps and the Dow by 670bps. The fund estimates that redemption fees added $15.5 million, or approximately 0.90% of NAV performance, but carries substantial concentration and private-market valuation risk, with indirect SpaceX exposure representing 21.49% of the portfolio.

Analysis

The reported excess return is not evidence of repeatable security selection: roughly 90bp came from redemption fees, a non-recurring transfer from exiting holders that can reverse if flows normalize or turn into sustained outflows. More importantly, the fund's private sleeve is held through SPVs, so NAV can lag the economic value of the underlying shares; secondary-market discounts, SPV fee layers, and restricted-sale periods can produce a persistent gap between XOVR's trading price and realizable asset value. This is a flow-and-structure trade, not a clean proxy for a listed SpaceX.

Near term, publicity around crossover access could attract advisor and retail flows, tightening any XOVR discount and supporting its most visible underlying exposure. The unfavorable second-order effect is that a larger ETF asset base may make future redemptions more disruptive: liquid public positions are likely sold first while less-liquid SPV interests remain, mechanically increasing private-asset concentration and potentially widening the discount during risk-off episodes. NDAQ has little direct earnings sensitivity; any benefit is limited to marginal ETF trading volumes rather than a meaningful franchise catalyst.

The consensus risk is likely underpricing valuation-mark uncertainty after a liquidity event. A public reference price does not guarantee that SPV-held shares can be monetized at that price, particularly through lockups, transfer restrictions, or a weak post-IPO trading tape. The thesis is falsified if published portfolio disclosures show declining private-sleeve concentration, independently marked NAVs consistently converging with quoted underlying values, and durable net inflows without a widening market-price/NAV spread over the next 1-3 months.

Key Decisions for Investors

• No standalone NDAQ trade: monitor ETF-volume data, but require a measurable acceleration in U.S. ETF net issuance and exchange market-share gains before attributing earnings upside to this product.
• Treat XOVR as a tactical flow vehicle rather than core private-market exposure; only consider a small long if its market-price discount to independently disclosed NAV exceeds 5% and creation/redemption activity is functioning normally. Target discount compression over 1-3 months; exit if the discount widens beyond 10% or private-sleeve concentration rises.
• For investors seeking listed SpaceX exposure, prefer SPCX only after confirming direct holding structure, lockup status, and post-IPO liquidity; avoid assuming XOVR and SPCX have equivalent beta. A 15-20% decline in the underlying public share price or evidence of SPV markdowns would invalidate a crossover-premium trade.
• Set an alert for quarterly holdings disclosure: a rise in illiquid/private exposure above the current level alongside net outflows is a bearish signal for XOVR's discount and liquidity profile, favoring avoidance rather than a short absent borrow and reliable NAV marks.